Our New Drug and Diagnostic Approach Could Be Used for at Least Five Types of Cancers

Type of Cancer
Number of Diagnoses in the U.S. per Year
Acute Myeloid Leukemia (AML) 21,380
Myelodysplastic Syndromes (MDS) 10,000+
Ovarian Cancer 22,400
Triple Negative Breast Cancer   34,776
Non-Small Cell Lung Cancer 224,000

These cancers have shown potential sensitivity to our drug and have few targeted therapies currently available. AML and MDS showed the highest sensitivity so we are focusing on those first.


Sources: Cowen and Company. Therapeutic Categories Outlook. October 2014; SEER.Cancer.gov, Nov. 2015; and Needham and Company. AML Drug Development Update, April 2016.